SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently gripped by an extreme short squeeze, with community discussion centered on its highly constrained float and reports that a small group of institutional holders control a majority of the shares. While many traders are enjoying significant gains from the stock's parabolic ascent, others are cautioning that the rampant volatility, frequent trading halts, and the potential for a share offering or institutional profit-taking make this a high-stakes, dangerous game of musical chairs.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is experiencing a surge in trading volume and bullish sentiment driven by CFO comments confirming production ramp-ups and multiple purchase orders that validate the company's optical engine technology for hyperscale AI. Community discussions are centered on a potential short squeeze, a rejection of recent negative research reports, and mounting optimism that the stock is undergoing an institutional re-pricing phase as it transitions from a developmental play to revenue execution.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as frustrated investors grapple with a relentless semiconductor sector rally, questioning why the stock continues to bleed despite market volatility. Community discourse is heavily polarized between long-term bears betting on an inevitable bubble burst and others debating whether to capitulate or double down on their positions amid consistent downward price pressure.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to strong bullish momentum as investors shift their focus toward the company's role in inference and agentic AI workloads. The community is actively debating the stock's valuation, its potential to reach the trillion-dollar market cap club, and the technical strength of the ongoing rally.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United Airlines is experiencing significant market volatility as it navigates operational headwinds from severe winter weather, which has triggered widespread flight cancellations and put pressure on near-term revenue. Investors are closely monitoring the company's management strategy, including its recent push for premiumization and fleet investments, while also weighing concerns over rising fuel costs and the broader impact of geopolitical instability on the sector.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 ETF is experiencing high volatility as investors react to a barrage of conflicting headlines regarding peace talks, blockade status, and potential escalation in the Middle East. The community remains deeply polarized, with many traders expressing frustration over perceived market manipulation and headline-driven price swings while debating the timing of a potential deal versus a broader conflict.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is facing significant volatility as investors weigh the potential of its new CX Enterprise agentic AI platform and a major $25 billion stock buyback program against ongoing software sector pressure and AI disruption fears. While the community remains deeply divided between those viewing the stock as a deeply undervalued generational opportunity and those concerned about long-term structural threats, the primary focus remains on whether these capital-heavy initiatives will finally catalyze a definitive trend reversal.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust is experiencing heightened volatility as market participants fixate on the expiration of ceasefire talks in the Middle East and the potential for a geopolitical escalation. The community is actively debating the reliability of diplomatic headlines versus the risk of renewed conflict, with retail investors expressing frustration over the market's resilience against negative news cycles.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is currently in the spotlight following a strong earnings beat, where they surpassed revenue expectations and raised their full-year profit outlook. Community sentiment is mixed as bulls celebrate the stock's recovery and the announcement of a multi-billion dollar share buyback, while bears continue to scrutinize long-term healthcare cost pressures and regulatory headwinds.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is experiencing significant market attention following its earnings report and the strategic $23 billion acquisition of Exact Sciences. While the company faces pressure from adjusted growth guidance and ongoing litigation concerns, investors remain focused on long-term value, with many discussing the stock's potential for a re-rating as they navigate the integration of its expanded diagnostics footprint.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A U.S. bankruptcy judge has cleared 23andMe’s $305 million sale to TTAM Research, a nonprofit led by co-founder Anne Wojcicki, rejecting California’s attempt to delay the deal over privacy concerns.&nbsp;Judge Brian Walsh said California’s appeal is likely to fail and that consumers remain free to delete their data, according to a Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/california-fails-stop-23andme-founder-re-acquiring-company-2025-07-07/">report</a>.On July 2,&nbsp;<a href="https://stocktwits.com/symbol/MEHCQ">23andMe</a> confirmed the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/23and-me-co-founder-anne-wojcicki-wins-back-company-in-305-m-deal-beating-regeneron-s-bid/chF03X0RTJd">sale</a> of “substantially all” of its assets, including its core Personal Genome Service, research unit, and Lemonaid Health, to TTAM.&nbsp;The transaction, approved by the U.S. Bankruptcy Court for the Eastern District of Missouri, is expected to close in the coming weeks.California, backed by states like New York and Texas, argued the sale violated genetic privacy laws and could lead to the unauthorized transfer of DNA data.&nbsp;The state said 1.8 million California customers were affected.&nbsp;Walsh dismissed the concerns, citing existing user rights and TTAM’s commitment to upholding privacy policies.TTAM outbid&nbsp;<a href="https://stocktwits.com/symbol/REGN">Regeneron Pharmaceuticals'</a>&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/regeneron-to-buy-assets-of-23andme/ch0cpqfRbFD">$256 million offer</a> in a court-supervised process.&nbsp;Wojcicki, who resigned as CEO earlier this year to make an independent bid, said operating as a nonprofit will better align with 23andMe’s mission to promote public understanding of DNA.On Stocktwits, retail sentiment for&nbsp;23andMe was ‘bearish’ amid ‘extremely low’ message volume.23andMe’s stock has risen 35.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

23andMe Founder and Board Member Anne Wojcicki appears during a House Committee on Oversight and Government Reform hearing on June 10, 2025 in Washington, DC. 

23andMe’s $305M Sale To Co-Founder Wojcicki Approved: California Loses Legal Battle Over DNA Privacy

A U.S. bankruptcy judge ruled that California's appeal to block the deal was unlikely to succeed, rejecting claims that the sale violated state genetic privacy laws.

Equity

23andMe Holding said Tuesday that a U.S. bankruptcy court has approved the sale of “substantially all” its assets to TTAM Research Institute, a California-based nonprofit led by company co-founder and former CEO Anne Wojcicki.&nbsp;The $305 million transaction is expected to close in the coming weeks.The deal, approved by the U.S. Bankruptcy Court for the Eastern District of Missouri, includes the company’s core Personal Genome Service, research services, and its telehealth subsidiary Lemonaid Health.&nbsp;TTAM will assume control of the company’s ongoing operations with plans to relaunch it as a nonprofit.The court’s approval concludes a months-long sale process that began after&nbsp;<a href="https://stocktwits.com/symbol/MEHCQ">23andMe</a>&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/23andme-stock-jumps-after-court-approves-bankruptcy-asset-sale/chJ322ARbEo">filed for Chapter 11</a> bankruptcy in March.&nbsp;At that time, the company secured initial court authorization for key motions, including wage payments, vendor compensation, and a $35 million debtor-in-possession financing deal with JMB Capital Partners.&nbsp;A formal sale process followed, led by Moelis &amp; Co., which required any buyer to honor 23andMe’s existing consumer privacy policies.In May,&nbsp;<a href="https://stocktwits.com/symbol/REGN">Regeneron Pharmaceuticals</a>&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/regeneron-to-buy-assets-of-23andme/ch0cpqfRbFD">agreed to acquire</a> most of 23andMe’s assets for $256 million.&nbsp;That bid excluded Lemonaid Health and was positioned to expand Regeneron’s capabilities in genetics-driven drug development.&nbsp;However, Wojcicki’s TTAM offer ultimately prevailed in the court-supervised auction.TTAM has committed to&nbsp;upholding 23andMe’s customer privacy standards and stated that it will implement additional safeguards.&nbsp;Customers will receive advance notice ahead of the transaction’s close, with information on how to delete their data or opt out of research.&nbsp;Wojcicki, who resigned as CEO earlier this year to position herself as an independent bidder, said the nonprofit structure will better support 23andMe’s founding mission.&nbsp;“As a nonprofit, TTAM will be a champion of improving our knowledge of DNA – the code of life – for the public good,” she said. “Individuals should be empowered to have choice and transparency with respect to their genetic data.”On Stocktwits, retail sentiment for 23andMe Holding was ‘bullish’ amid ‘low’ message volume.Shares of Regeneron Pharmaceuticals ended up 1.9% on Tuesday. However, the stock declined 25.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

23andMe Co-Founder Anne Wojcicki Wins Back Company In $305M Deal, Beating Regeneron’s Bid

The deal encompasses 23andMe’s core genome testing service, research operations, and Lemonaid Health, with TTAM set to relaunch the company as a nonprofit organization committed to upholding existing data privacy policies.

Chrome Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcicki in 2006 and is headquartered in San Francisco, CA.

MEHCQ
23andMe Holding Co

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest MEHCQ News

MEHCQ23andMe Holding Co